The company says that it has discovered a potentially attractive gold deposit at Alturas in Chile. It’s located in one of company’s core areas, the Andean region of Chile. The reserve is primarily oxide, similar to Barrick’s Veladero mine. It could, however, have significantly higher grades. The company says that given its significant potential, it’s moving quickly on the discovery and expects to report an initial resource estimate with its 2015 full-year results.
UBS say $3 this should be in $6 to $10 range?
29-May-15 UBS Upgrade Neutral to Buy
Maricunga mine resumed earlier this month, ahead of the anticipated June restart target. Operations were partially suspended on March 25 following an extreme weather event in northern Chile, which caused heavy damage to local infrastructure. The ADR plant operated throughout the restart effort, producing gold from existing material in the heap leach.
Paul Pockros, a hematologist at the Scripps Clinic in La Jolla, also emphasized that HCV drugs need to demonstrate continued efficacy with lower treatment times in harder-to-treat patients in order to qualify for regulatory approval. He said: “The FDA really doesn’t want to accept any relapse at all.”
Achillion understands this issue. It now plans to conduct a study of its HCV treatment in harder-to-treat patient groups, including those affected by advanced fibrosis, according to company spokesman Glenn Schulman. He said: “Next-generation regimens, including ours, will have to simplify and shorten treatment duration across broad patient populations.”
SPARTA Phase 2 program which evaluated 6 weeks durations with once-daily regimens of ACH-3102 and ACH-3422, with or without sovaprevir, for treatment naïve genotype 1 HCV patients. Meaning sofosbuvir-sparing regimens that will leverage shorter durations of sofosbuvir in combination with ACH-3102 is already evaluated for 4 weeks regimen, and data shall be anytime soon.
Johnson & Johnson obviously has a global sales force that could get ramped up and could drive sales for this drug, and actually make a go of it against Gilead. There's a lot that needs to happen between here and there.
Specifically you've got a situation where Johnson & Johnson has now licensed global rights to Achillion HCV, Hep-C pipeline. That pipeline includes ACH3102, and ACH3102 is a next generation, S5A inhibitor. Basically it targets the same target that Ledipasvir does in Gilead's top selling Harvoni -- which is a mashup of that Ledipasvir and Sovaldi.
So, the idea is "Can we come up with a better combination that would deliver similar efficacy, but do it in a shorter treatment duration?" In very small trials, they've been able to effectively cure patients in both six weeks and eight weeks by combining ACH3102 and Sovaldi. That has gotten people's attention.
It's like, if J&J license 3102 -- which it has -- and then it can take that and combine it with -- it acquired some drugs that worked similarly to the way Sovaldi does, last fall when it bought Alios and got their nuke pipeline -- So, they can combine it with that, then possibly they can come up with a pan genotype drug that would outperform, or equally perform with Harvoni, but require patients to take it for less time.
FDA rescinds 'breakthrough' status for Merck's hepatitis C drug meaning something seriously wrong and that was a the rare move by the FDA follows the market debut of two new hepatitis C treatments in the last year.
HCV is a global epidemic associated with burdensome complications. Research suggests that the treatment paradigm for HCV will evolve from the current interferon-based therapies to interferon-free combination treatments that deliver high cure rates for a majority of HCV patients, minimal side effects, shortened treatment durations of 12 weeks or less, and a competitive cost. Due to the widespread infection of HCV and demand for these improved therapies, multiple estimates forecast the global market for HCV treatment will reach $20 billion annually by the end of the decade. The market is projected to persist through 2030 due to the low rates of HCV diagnosis globally, which will require intensive screening and linkage to care efforts during the initial introduction of interferon-free treatments, and the large number of patients requiring care from a limited number of specialty physicians.